# US 10,246,512 B2 · IL-2R beta/common gamma chain antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,246,512 B2
- Document ID: US10246512B2
- Status: Granted
- Kind: B2
- Application number: 15/922,921
- Filed: 2018-03-16
- Published: 2018-07-26
- Granted: 2019-04-02
- Earliest claimed: 2015-08-06
- Assignees: Agency for Science, Technology and Research
- Applicants: Agency for Science, Technology and Research
- Inventors: Cheng-I Wang; Peter Brauer; Siok Ping Yeo; Hwee Ching Tan; John Edward Connolly
- Web page: https://patentgrep.com/patent/US10246512B2

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 38/2013: {IL-2}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/112: Retroviridae (F), e.g. leukemia viruses
- C07K 16/246: {IL-2}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 38/1709: {from mammals}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/60: characterized by non-natural combinations of immunoglobulin fragments
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Anti-CD122 and/or γc antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.

## Claims

### Claim 1

An isolated antibody or antigen binding fragment, which specifically binds to CD122 and common γ chain (γc), wherein the antibody or antigen binding fragment is an IL-2 receptor agonist, and wherein the antibody or antigen-binding fragment comprises:
(a) an antigen-binding fragment which binds to CD122, comprising:
(i) a light chain variable region comprising the
following CDRs:
LC-CDR1:
(SEQ ID NO: 2)
TGTSSDIGHYDFVS
LC-CDR2:
(SEQ ID NO: 3)
DINNRPS
LC-CDR3:
(SEQ ID NO: 4)
SAYTSSDTLV;
and
(ii) a heavy chain variable region comprising the
following CDRs:
HC-CDR1:
(SEQ ID NO: 36)
NYYMH
HC-CDR2:
(SEQ ID NO: 37)
AIMPSRGGTSYPQKFQG
HC-CDR3:
(SEQ ID NO: 38)
GEYYYDSSGYYY;
and
(b) an antigen-binding fragment which binds to common γ chain, comprising:
(i) a light chain variable region comprising the
following CDRs:
LC-CDR1:
(SEQ ID NO: 68)
RSSQSLLHSNGYNYLD
LC-CDR2:
(SEQ ID NO: 69)
LGSNRDS
LC-CDR3:
(SEQ ID NO: 70)
MQGTHWPWT;
and
(ii) a heavy chain variable region comprising the
following CDRs:
HC-CDR1:
(SEQ ID NO: 48)
GYYWS
HC-CDR2:
(SEQ ID NO: 49)
EINHSGSTNYNPSLKS
HC-CDR3:
(SEQ ID NO: 77)
SPGGYSGGYFQH.

### Claim 2 (depends on 1)

The isolated antibody or antigen binding fragment according to claim 1, wherein the antigen-binding fragment which binds to CD122 comprises a light chain variable region sequence and a heavy chain variable region sequence, wherein:
the light chain variable region sequence has at least 70% sequence identity to the light chain variable region sequence of SEQ ID NO:1, and
the heavy chain variable region sequence has at least 70% sequence identity to the heavy chain variable region sequence of SEQ ID NO:35.

### Claim 3 (depends on 1)

The isolated antibody or antigen binding fragment according to claim 1, wherein the antigen-binding fragment which binds to common γ chain comprises a light chain variable region sequence and a heavy chain variable region sequence, wherein:
the light chain variable region sequence has at least 70% sequence identity to the light chain variable region sequence of SEQ ID NO:67, and
the heavy chain variable region sequence has at least 70% sequence identity to the heavy chain variable region sequence of SEQ ID NO:76.

### Claim 4 (depends on 1)

The isolated antibody or antigen binding fragment according to claim 1, which binds to the IL-2 receptor comprising a complex of CD122 and common γ chain.

### Claim 5 (depends on 1)

The isolated antibody or antigen binding fragment according to claim 1, provided in scFv-KiH-Fc or CrossMab format.

### Claim 6 (depends on 1)

The isolated antibody or antigen binding fragment according to claim 1, conjugated to a drug moiety or a detectable moiety.